Keyphrases
Long-term Survival
100%
Patient Survival
100%
Real Patients
100%
Advanced Melanoma
100%
BRAF Inhibitor (BRAFi)
100%
Brain Metastases
50%
Median Overall Survival
50%
Long-term Survivors
50%
Everyday Practices
25%
Overall Survival
25%
Clinical Trials
25%
Tumor
25%
Patient Characteristics
25%
Baseline Characteristics
25%
Median Progression-free Survival
25%
5-year Survival
25%
Liver Metastasis
25%
BRAFV600
25%
3-year Survival
25%
PS-1
25%
Elevated LDH
25%
Advanced Cutaneous Melanoma
25%
Metastatic Site
25%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
25%
ECOG PS 2
25%
Pharmacology, Toxicology and Pharmaceutical Science
Mitogen Activated Protein Kinase Kinase Inhibitor
100%
Long Term Survival
100%
Melanoma
100%
Overall Survival
75%
Lactate Dehydrogenase
75%
Brain Metastasis
50%
Clinical Trial
25%
Population Study
25%
Progression Free Survival
25%
Liver Metastasis
25%
Cutaneous Melanoma
25%
Neoplasm
25%
Diseases
25%
Immunology and Microbiology
Long Term Survival
100%
Overall Survival
75%
Population Research
25%
Progression Free Survival
25%